Shares of$Instil Bio (TIL.US)$surged over 60% on Friday after Baird raised its price target to $180, signaling a potential 146% upside. Despite this rally, retail investors remain cautious. Baird's optimism is driven by promising developments in Instil’s PD-L1xVEGF bispecific antibody, especially following positive data from peers like Akeso and Summit. Analysts believe this drug class has strong potentia...
Baird's optimism is driven by promising developments in Instil’s PD-L1xVEGF bispecific antibody, especially following positive data from peers like Akeso and Summit. Analysts believe this drug class has strong potentia...
going
down
again
No comment yet